Menu Menu


COVID-19 Research Pipeline


Registered/ Published






As at 27 May 2022
FILTERED BY > Consumer Panel Clear filter

Communique #62

31 March, 2022
Click for the latest Taskforce news:   

Communique #60

17 March, 2022
Click for the latest Taskforce news: 

Consumer Panel Recruitment

10 March, 2022
Would you like to use your experience to improve the care of Australians with COVID-19? The National COVID-19 Clinical Evidence Taskforce is seeking two new members to join...

Communique #44

24 May, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendations Baricitinib upgraded to a conditional recommendation The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed the latest evidence for...

Communique #43

10 May, 2021
WEEK IN REVIEW Taskforce reaches consensus on first IPC recommendations On Monday 03 May, the Taskforce provided the Infection Control Expert Group (ICEG) with the final draft of the...

🎥 WEBINAR: Living Evidence, COVID-19 and consumers?

4 May, 2021
Learn how the Taskforce develops living guideline recommendations and the role of consumers If you missed the recent webinar hosted by Consumers Health Forum of Australia, you can...

Webinar: Living Evidence and consumers

22 April, 2021
Are you interested in developing a better understanding of how clinical guidelines can be kept up-to-date with the latest evidence as new research emerges? The Taskforce is proud...

Communique #40

18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...

Seeking consumers and carers with lived experience of COVID-19

24 February, 2021
Share your lived experiences of COVID-19 and contribute to the national guidelines The Taskforce welcomes people who have been affected by COVID-19 to join the Consumer Panel.  The...

Weekly Communique #34

3 December, 2020
WEEK IN REVIEW Updates to the living guideline New recommendations published this week cover: Dutasteride Oestrogen-containing therapies (including menopause hormone therapies (MHT) and contraceptives). These recommendations were developed by the...

Weekly Communique #30

5 November, 2020
WEEK IN REVIEW Bromhexine hydrochloride added to list of 'only in clinical trials' The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed two new trial results for bromhexine hydrochloride (commonly...

Weekly Communique #24

24 September, 2020
WEEK IN REVIEW Six-month milestone for the Taskforce There was great anxiety among clinicians back in March, as Australia prepared to face the first wave of the COVID-19 pandemic and the...

Weekly Communique #15

23 July, 2020
WEEK IN REVIEW Rooming-in recommendation The Pregnancy and Perinatal Care Panel have made their third conditional recommendation. This week's concerns Rooming-in: For women with COVID-19 who have given birth,...

Weekly Communique #14

16 July, 2020
WEEK IN REVIEW This week we experienced a shift in the level of alert among the clinicians who form Australia's frontline healthcare response to COVID-19, particularly in Victoria....

Weekly Communique #9

11 June, 2020
WEEK IN REVIEW Time to acknowledge our expert volunteer contributions It's hard to believe that it's been 12 weeks since the Taskforce's first panel meeting. What began with...

Weekly Communique #7

28 May, 2020
WEEK IN REVIEW The Taskforce has issued a consensus recommendation to consider increased-dose venous thromboembolism (VTE) prophylaxis for adults with severe to critical COVID-19. This recommendation was developed with input from thrombosis specialists on the Taskforce's...